CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D009102: Multiple Organ Failure NIH

(Synonyms: Multiple Org, Multiple Organ Failure)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug1004 Saline Control Wiki 0.58
drug831 Pectin Wiki 0.58
drug1355 no intervention-mechanistic study Wiki 0.58
drug36 Acacia Senegal Wiki 0.58
drug666 MSC Treatment Wiki 0.58

Correlated MeSH Terms (9)

Name (Synonyms) Correlation
D018746 Systemic Inflammatory Response Syndrome NIH 0.33
D058186 Acute Kidney Injury NIH 0.24
D013577 Syndrome NIH 0.08
D055371 Acute Lung Injury NIH 0.08
D012127 Respiratory Distress Syndrome, Newborn NIH 0.07
D012128 Respiratory Distress Syndrome, Adult NIH 0.06
D011014 Pneumonia NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.03
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.24
HP:0002090 Pneumonia HPO 0.04

There are 3 clinical trials

Clinical Trials

1 Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19

The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.

NCT04316884 COVID-19 Organ Dysfunction Syndrome Sepsis Organ Dysfunction Syndrome, Multiple Septic Shock Acute Kidney Injury Acute Respiratory Distress Syndrome
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Acute Kidney Injury Syndrome Multiple Organ Failure Systemic Inf Systemic Inflammatory Response Syndrome
HPO:Acute kidney injury

Primary Outcomes

Description: KDIGO AKI score

Measure: Acute Kidney Injury

Time: During Intensive Care, an estimated average of 10 days.

Secondary Outcomes

Description: Acute Respiratory Distress Syndrome yes/no

Measure: ARDS

Time: During intensive care, an estimated average of 10 days.

Description: Death within 30 days of ICU admission

Measure: 30 day mortality

Time: 30 days

Description: Death within 1 year of ICU admission

Measure: 1 year mortality

Time: 1 year

Description: Development of Chronic Kidney Disease

Measure: Chronic Kidney Disease

Time: 60 days and 1 year after ICU admission

Description: Sequential Organ Failure Score as a continuous variable

Measure: SOFA-score

Time: During Intensive Care, an estimated average of 10 days.

2 What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study)

This study aims to use the regenerative and repair abilities of stem cells to fight against the harmful effects of the novel coronavirus Covid-19 and therefore develop a treatment strategy. It is known that fatalities from this virus is largely caused by its damage to lungs and other organs. As the disease progresses, these organs fail and lead to mortality. Our hope is that the stem cell transplantation from healthy donors will repair the damage caused by the virus and result in a healthy recovery.

NCT04392778 Covid19 Pneumonia Multiple Organ Failure Corona Virus Infection Biological: MSC Treatment Biological: Saline Control
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia Multiple Organ Failure

Primary Outcomes

Description: Improvement of clinical symptoms related to Covid-19 infection (fever, pneumonia, shortness of breath)

Measure: Clinical improvement

Time: 3 months

Secondary Outcomes

Description: Improvement of lungs assessed by CT Scan

Measure: Lung damage improvement

Time: 3 months

Description: Negative, measured by RT-PCR laboratory tests for the virus

Measure: Sars-Cov-2 viral infection laboratory test

Time: 3 months

Description: Cell types and numbers

Measure: Blood test

Time: 3 months

3 Multi-organ Failure in SARS-CoV2: Identifying Mechanisms and Potential Therapeutic Targets

In the United Kingdom, there are currently 138,000 confirmed patients with coronavirus, causing 18,738 deaths. Whilst the disease may be mild in the majority of patients, a significant proportion of patients require intensive care therapy and a ventilator due to lung injury. In addition to lung injury/failure (acute respiratory distress syndrome (ARDS)), around 50% of patients admitted to intensive care develop acute kidney injury (AKI) (requiring advanced support via haemofiltration) and multi-organ failure. It is unclear why patients suffering from COVID-19 develop such severe lung injury (requiring life support or ventilation) or indeed why patients develop other organ dysfunction such as kidney injury. The investigators hypothesis that this may due to an over-reaction of the immune system particularly in the lungs. This then results in the release of various mediators and biological messengers which can be pushed into the blood bloodstream (exacerbated by positive pressure generated by the ventilator). These mediators then travel, via the blood, to other organs such as the kidney where they cause inflammation and injury of cells, resulting in organ failure. At the Imperial College London (specifically at the Hammersmith Hospital campus) the investigators are in the unique position to investigate the pathophysiology of multi-organ failure as we are a referral centre for patients with COVID-19 who have developed renal and multi-organ failure (the hospital has accepted a number of these patients from various hospitals across the region). The Division of Anaesthetics, Pain Medicine and Intensive Care at Imperial College London, headed by Professor Masao Takata, has an international reputation, investigating the mechanisms of organ injury and failure (particularly lung injury) in critical care patients (non-viral causes). The investigators would like to apply well-established methods to try and further the scientific community's knowledge of this severe and deadly viral condition. The investigators hope that this would lead to the development of medication that would treat this deadly virus.

NCT04399603 COVID Other: no intervention-mechanistic study
MeSH:Multiple Organ Failure

Primary Outcomes

Description: This will involve measurement of microvesicles in blood

Measure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19

Time: 18 months

Description: This will involve measurement of microvesicles in bronchoalveolar lavage fluid

Measure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19

Time: 18 months

Description: This will involve measurement of microvesicles in urine

Measure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19

Time: 18 months

Secondary Outcomes

Description: The aforementioned inflammatory markers will be correlated with level fo lung injury which will be based upon the level of oxygen required by patients.

Measure: Correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement)

Time: 18 months

Description: The aforementioned inflammatory markers will be measured in renal outcomes (creatinine and urine output) and cardiovascular markers (e.g. natriuretic peptides (BNP and NT pro-BNP) and Troponin).

Measure: Correlation of circulating inflammatory mediators with renal and cardiovascular markers

Time: 18 months

Measure: Assess the role of inflammatory mediators obtained from patients in the development of renal injury using in vitro models (i.e. applying these inflammatory mediators isolated from these clinical samples on kidneys cells in a petri dish)

Time: 18 months

HPO Nodes